

MannKind to Present at the Jefferies 2011 Global Healthcare Conference

VALENCIA, Calif., May 31, 2011 (BUSINESS WIRE) -- MannKind Corporation (Nasdaq: MNKD), focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011 at 4:00 PM (ET) in New York.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at <u>www.mannkindcorp.com</u>.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA[®], is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind is also evaluating an investigational cancer immunotherapy product, MKC1106-MT, in a phase 2 clinical trial. MannKind maintains a website at <u>www.mannkindcorp.com</u> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation Matthew J. Pfeffer, 661-775-5300 Corporate Vice President and Chief Financial Officer <u>mpfeffer@mannkindcorp.com</u>